Welcome to CDC Stacks | Characteristics of antimicrobial studies registered in the USA through ClinicalTrials.Gov - 29689 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Characteristics of antimicrobial studies registered in the USA through ClinicalTrials.Gov
Filetype[PDF - 337.00 KB]


Details:
  • Pubmed ID:
    23726436
  • Pubmed Central ID:
    PMC3714326
  • Description:
    Increasing rates of antimicrobial-resistant infections and the dwindling pipeline of new agents necessitate judicious, evidence-based antimicrobial prescribing. Clinical trials represent a vital resource for establishing evidence of safety and efficacy, which are crucial to guiding antimicrobial treatment decisions. The objective of this study was to comprehensively evaluate the characteristics of antimicrobial research studies registered in ClinicalTrials.gov. Primary outcome measures, funding sources, inclusion criteria and the reporting of study results were evaluated for 16055 antimicrobial studies registered in ClinicalTrials.gov as of mid 2012. Interventional studies accounted for 93% of registered antimicrobial studies. Clinical trials of drugs (82%) and biologics (9%) were most common. Antibacterial, antiviral and antifungal studies accounted for 43%, 41% and 16% of drug trials, respectively. Among interventional drug trials, 73% featured randomised allocation to study arms and 71% included measures of safety and/or efficacy as primary endpoints. Children were eligible for enrolment in 26% of studies. Among the studies, 60% were sponsored primarily by non-profit organisations, 30% by industry and 10% by the federal government. Only 7% of studies reported results; however, 71% of these were sponsored primarily by industry. Antimicrobial studies commonly incorporated elements of high-quality trial design, including randomisation and safety/efficacy endpoints. Publication of study results and updating of ClinicalTrials.gov should be encouraged for all studies, with particular attention paid to research sponsored by non-profit organisations and governmental agencies. Leveraging the application of these data to guide the careful selection of antimicrobial agents will be essential to preserve their utility for years to come.

  • Document Type:
  • Collection(s):
  • Funding:
    U01 AI074419/AI/NIAID NIH HHS/United States
    U01 AI074419-01/AI/NIAID NIH HHS/United States
    U01A1082482/PHS HHS/United States
    U01AI082184-01/AI/NIAID NIH HHS/United States
    U18-IP000303-01/IP/NCIRD CDC HHS/United States
No Related Documents.
You May Also Like: